Advanced Imaging in Prostate Cancer Management: Current Status and Future Perspectives
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 5212
Special Issue Editors
Interests: MRI; MR-guided radiotherapy; medical imaging
Interests: MR-guided radiotherapy; prostate cancer; radiation oncology
Interests: urology; prostate cancer; surgery
Interests: PET; nuclear medicine
Interests: mpMRI; diagnosis
Special Issue Information
Dear Colleagues,
Advanced imaging has been playing an increasingly important role in the management of prostate cancer (PCa). For instance, multi-parametric MRI (mpRI) defined in The Prostate Imaging-Reporting and Data System (PI-RADS) is a novel promising tool for the diagnosis of prostate cancer that might help to reduce overdiagnosis of insignificant prostate cancer. mpMRI-targeted and PSMA-targeted PET biopsies are both known to have increased the detection rate and diagnostic accuracy of clinically significant prostate cancer. Together, they improve risk stratification and help in the selection of low-risk PC patients for active surveillance. Individually, mpMRI is effective in T staging by assessment of peri-prostatic tumor infiltration while PSMA-PET is useful in the evaluation of lymph node (N-staging) and distant metastasis (M-staging). The emerging utility of integrated PET/MRI is gaining importance as a multi-modality approach in the comprehensive management of PCa.
Besides diagnosis, MRI and PET have also recently contributed to the advancement of therapeutics for PCa, such as in radiation therapy, focal ablative therapy, and surgery. MRI-aided or MRI-only radiotherapy treatment planning has been increasingly adopted in routine clinical practice, while its utilization has yet to be standardized. MRI-guided adaptive radiotherapy (MRgART) empowered by the introduction of MRI-integrated linear accelerators (MR-LINAC) represents an innovative PC treatment technique, which hopefully will further improve treatment outcomes and reduce toxicities. On the other hand, PSMA-PET has gained a definitive role in the management of biochemical recurrence after primary cancer treatment and early identification of oligometastatic disease which is most critical in determining the chance of cure by either salvage radiotherapy or salvage lymph node dissection. Recent advancements in radiomics and artificial intelligence are also facilitating imaging markers in combination with other biomarkers in PCa management.
This Special Issue aims at providing a comprehensive picture of this lively research area by gathering contributions covering all aspects related to the use of advanced imaging in PCa management. We encourage the submissions of both original and review articles, including but not limited to technical, experimental, translational, and clinical studies.
Dr. Jing Yuan
Dr. Darren M. C. Poon
Dr. Peter Ka-Fung Chiu
Dr. Garrett Chi Lai Ho
Dr. Gladys Goh Lo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mpMRI
- PET
- prostate cancer
- diagnosis
- prognosis
- treatment response
- precision medicine
- imaging biomarkers
- artificial intelligence
- radiomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.